KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Net Cash Flow (2016 - 2026)

Bristol Myers Squibb has reported Net Cash Flow over the past 18 years, most recently at -$587.0 million for Q1 2026.

  • Quarterly Net Cash Flow fell 227.06% to -$587.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.4 billion through Mar 2026, down 187.62% year-over-year, with the annual reading at -$324.0 million for FY2025, 68.7% up from the prior year.
  • Net Cash Flow was -$587.0 million for Q1 2026 at Bristol Myers Squibb, up from -$5.5 billion in the prior quarter.
  • Over five years, Net Cash Flow peaked at $3.9 billion in Q4 2023 and troughed at -$5.5 billion in Q4 2025.
  • The 5-year median for Net Cash Flow is -$587.0 million (2026), against an average of -$279.7 million.
  • Year-over-year, Net Cash Flow crashed 2768.97% in 2022 and then surged 285.59% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $1.3 billion in 2022, then surged by 204.24% to $3.9 billion in 2023, then crashed by 32.84% to $2.6 billion in 2024, then crashed by 311.96% to -$5.5 billion in 2025, then soared by 89.35% to -$587.0 million in 2026.
  • Per Business Quant, the three most recent readings for BMY's Net Cash Flow are -$587.0 million (Q1 2026), -$5.5 billion (Q4 2025), and $3.1 billion (Q3 2025).